Inhibition of immunoproteasome reduces infarction volume and attenuates inflammatory reaction in a rat model of ischemic stroke

Cell Death and Disease

Volumn 6, Issue 1, 2015, Pages

  Chen, X ^a,b   Zhang, X ^b   Wang, Y ^b   Lei, H ^b   Su, H ^c   Zeng, J ^a   Pei, Z ^a   Huang, R ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF MACAU   (Macao)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CHYMOTRYPSIN; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 1BETA; LOW MOLECULAR MASS PEPTIDE 2; LOW MOLECULAR MASS PEPTIDE 7; PEPTIDE; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CYSTEINE PROTEINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUPEPTIN; LMP-2 PROTEIN; LMP7 PROTEIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN SUBUNIT; SMALL INTERFERING RNA; UBIQUITINATED PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN CORTEX; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL ACTIVATION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORPUS STRIATUM; CYTOPLASM; GENE SILENCING; IMMUNOREACTIVITY; IN VIVO STUDY; MACROPHAGE; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; UBIQUITINATION; WESTERN BLOTTING; ANIMAL; BRAIN INFARCTION; CEREBRAL ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY; PROTEIN SUBUNIT; PROTEIN TRANSPORT; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; ASTROCYTES; CEREBRAL INFARCTION; CYSTEINE ENDOPEPTIDASES; DISEASE MODELS, ANIMAL; GENE KNOCKDOWN TECHNIQUES; INFARCTION, MIDDLE CEREBRAL ARTERY; INFLAMMATION; INTERLEUKIN-1BETA; LEUPEPTINS; MALE; MICROGLIA; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEIN SUBUNITS; PROTEIN TRANSPORT; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING; STROKE; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITINATED PROTEINS;

EID: 84927654227     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.586     Document Type: Article

References (32)

1. Ahmad M, Graham SH. Inflammation after stroke: mechanisms and therapeutic approaches. Transl Stroke Res 2010; 1: 74-84.
2. Fietta P, Delsante G. Proteasomes and immunoproteasomes. Riv Biol 2010; 103: 29-50.
3. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994; 78: 773-785.
4. Zhang L, Zhang ZG, Zhang RL, Lu M, Adams J, Elliott PJ et al. Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 2001; 32: 2926-2931.
5. Williams AJ, Hale SL, Moffett JR, Dave JR, Elliott PJ, Adams J et al. Delayed treatment with MLN519 reduces infarction and associated neurologic deficit caused by focal ischemic brain injury in rats via antiinflammatory mechanisms involving nuclear factor-kappaB activation, gliosis, and leukocyte infiltration. J Cereb Blood Flow Metab 2003; 23: 75-87.
6. Wojcik C, Di Napoli M. Ubiquitin-proteasome system and proteasome inhibition: new strategies in troke therapy. Stroke 2004; 35: 1506-1518.
7. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of xperimental arthritis. Nat Med 2009; 15: 781-787.
8. Seifert U, Bialy LP, Ebstein F, Bech-Otschir D, Voigt A, Schroter F et al. Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 2010; 142: 613-624.
9. van Deventer S, Neefjes J. The immunoproteasome cleans up after Inflammation. Cell 2010; 142: 517-518.
10. Basler M, Dajee M, Moll C, Groettrup M, Kirk CJ. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol 2010; 185: 634-641.
11. Mishto M, Bellavista E, Santoro A, Stolzing A, Ligorio C, Nacmias B et al. Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains. Neurobiol Aging 2006; 27: 54-66.
12. Orre M, Kamphuis W, Dooves S, Kooijman L, Chan ET, Kirk CJ et al. Reactive glia show increased immunoproteasome activity in Alzheimer's disease. Brain 2013; 136: 1415-1431.
13. Lu L, Wang H. Transient focal cerebral ischemia upregulates immunoproteasomal subunits. Cell Mol Neurobiol 2012; 32: 965-970.
14. Ge P, Luo Y, Liu CL, Hu B. Protein aggregation and proteasome dysfunction after brain ischemia. Stroke 2007; 38: 3230-3236.
15. Arkhjamil Angeles GFHL, Immune and non-immune functions of the immunoproteasome. Front Biosci 2012; 17: 1904-1916.
16. Kremer M, Henn A, Kolb C, Basler M, Moebius J, Guillaume B et al. Reduced immunoproteasome formation and accumulation of immunoproteasomal precursors in the brains of lymphocytic choriomeningitis virus-infected mice. J Immunol 2010; 185: 5549-5560.
17. Hussong SA, Kapphahn RJ, Phillips SL, Maldonado M, Ferrington DA. Immunoproteasome deficiency alters retinal proteasome's response to stress. J Neurochem 2010; 113: 1481-1490.
18. Wehenkel M, Ban JO, Ho YK, Carmony KC, Hong JT, Kim KB. A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice. Br J Cancer 2012; 107: 53-62.
19. Groettrup M, Standera S, Stohwasser R, Kloetzel PM. The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome. Proc Natl Acad Sci USA 1997; 94: 8970-8975.
20. Klare N, Seeger M, Janek K, Jungblut PR, Dahlmann B. Intermediate-type 20S proteasomes in HeLa cells: "asymmetric" subunit composition, diversity and adaptation. J Mol Biol 2007; 373: 1-10.
21. Gohlke S, Kloss A, Tsokos M, Textoris-Taube K, Keller C, Kloetzel PM et al. Adult human liver contains intermediate-type proteasomes with different enzymatic properties. Ann Hepatol 2014; 13: 429-438.
22. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20: 84-91.
23. Doeppner TR, Mlynarczuk-Bialy I, Kuckelkorn U, Kaltwasser B, Herz J, Hasan MR et al. The novel proteasome inhibitor BSc2118 protects against cerebral ischaemia through HIF1A accumulation and enhanced angioneurogenesis. Brain 2012; 135: 3282-3297.
24. Sheng R, Zhang LS, Han R, Liu XQ, Gao B, Qin ZH. Autophagy activation is associated with neuroprotection in a rat model of focal cerebral ischemic preconditioning. Autophagy 2010; 6: 482-494.
25. Lin TN, He YY, Wu G, Khan M, Hsu CY. Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke 1993; 24: 117-121.
26. Xing S, Zhang Y, Li J, Zhang J, Li Y, Dang C et al. Beclin 1 knockdown inhibits autophagic activation and prevents the secondary neurodegenerative damage in the ipsilateral thalamus following focal cerebral infarction. Autophagy 2012; 8: 63-76.
27. Wu T, Wu H, Wang J, Wang J. Expression and cellular localization of cyclooxygenases and prostaglandin E synthases in the hemorrhagic brain. J Neuroinflammation 2011; 8: 22.
28. Yao X, Liu J, McCabe JT. Alterations of cerebral cortex and hippocampal proteasome subunit expression and function in a traumatic brain injury rat model. J Neurochem 2008; 104: 353-363.
29. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 2003; 179: 38-46.
30. Gozal D, Row BW, Kheirandish L, Liu R, Guo SZ, Qiang F et al. Increased susceptibility to intermittent hypoxia in aging rats: changes in proteasomal activity, neuronal apoptosis and spatial function. J Neurochem 2003; 86: 1545-1552.
31. Farout L, Lamare MC, Cardozo C, Harrisson M, Briand Y, Briand M. Distribution of proteasomes and of the five proteolytic activities in rat tissues. Arch Biochem Biophys 2000; 374: 207-212.
32. Keller JN, Huang FF, Zhu H, Yu J, Ho YS, Kindy TS. Oxidative stress-associated impairment of proteasome activity during ischemia-reperfusion injury. J Cereb Blood Flow Metab 2000; 20: 1467-1473.